Q-omics provides the consensus-scored PSENEN profile across patient tissues and cancer cell-line models. PSENEN expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PSENEN is differentially expressed in 11, with the highest sampling consensus in BLCA. Additionally, PSENEN RNA expression shows 18,144 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, BLCA, and THYM as cancer lineages where PSENEN shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSENEN — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSENEN survival associations across molecular data types. PSENEN RNA expression shows survival associations in the most cancer types (22), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSENEN RNA expression–survival associations across cancer types. High PSENEN expression shows unfavorable associations in KIRC, ACC, LIHC, LUAD, LGG and UVM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PSENEN RNA expression.
This table summarizes PSENEN tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for PSENEN. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSENEN shows lower tumor expression in KICH and higher tumor expression in BLCA, KIRP, KIRC, LIHC and LUAD. The BLCA box plot shows higher PSENEN RNA expression in tumor versus normal tissue (log2 FC = +1.139, t-test p < 0.001).
This table shows molecular features associated with PSENEN in patient tissues and cancer cell lines. In patient samples, PSENEN shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, PSENEN RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and SOFT_TISSUE.
